Biopartners Appoints Dr Conrad Savoy as CEO
Biopartners GmbH has announced the appointment of Dr Conrad Savoy as its new CEO and President of the Board from the 1st of May 2009. The change, which sees former CEO, Jean-Noël Treilles remain closely involved with the company in advisory consultancy role, is the result of a planned succession strategy following the purchase of the company by the Bioton Group S.A. in 2007.
Building on a track record of more than 18 years’ experience in development work in the pharmaceutical and biotech industry, leading several projects to EMEA approval, Dr Savoy joined Biopartners in 2001 as Head of Pharma Development. Initially heading up Biopartners’ growth hormone development portfolio, he was promoted to Chief Scientific Officer working closely with Mr Treilles after the company was acquired by Bioton, and appointed to the board at the same time. Prior to joining Biopartners, Dr Savoy spent 10 years at Hoffmann-La Roche Ltd in various senior positions in global drug development. He holds an MBA from the Open University Business School, United Kingdom, and a PhD from the University of Basel, Switzerland.
In March 2009, Jean-Noël Treilles stepped down as CEO after five years service during which time he steered the company successfully through the acquisition by Bioton, together with Biopartners’ former Chief Financial Officer, Walter Häusermann.
Other news from the department people
